Physician profile
William Morano
NPI 1548609969
$11,251.82
in general payments reported to CMS, 2019-2025
16 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.16 · 2020: $305 · 2021: $18.46 · 2022: $4,000 · 2023: $6,222 · 2024: $357 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $865.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,391.99 | 2022-2024 | Davinci Xi, Da Vinci Surgical System |
| Medical Device Business Services, INC. | $305.00 | 2020 | |
| Abbvie INC. | $127.62 | 2025 | |
| Boston Scientific Corporation | $83.34 | 2025 | Therasphere Administration Set |
| Stryker Corporation | $63.16 | 2019 | |
| Medtronic, INC. | $52.98 | 2025 | Ligasure, Transorb |
| Daiichi Sankyo INC. | $51.20 | 2024-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $27.21 | 2023 | Keytruda, Lynparza |
| Incyte Corporation | $24.86 | 2024 | Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $20.84 | 2024 | Tagrisso |
| Servier Pharmaceuticals LLC | $20.51 | 2024 | |
| Endomagnetics LTD | $18.46 | 2021 | |
| Kci USA, INC. | $16.76 | 2023 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Genentech USA, INC. | $16.64 | 2024 | Phesgo, Polivy, Tecentriq |
| Seagen INC. | $16.26 | 2023 | Tukysa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $14.99 | 2024 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Morano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.